AMINE OXIDASE (FLAVIN-CONTAINING) B

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 12:47:53 GMT 2023` Edited by `admin` on `Sat Dec 16 12:47:53 GMT 2023`
Protein Type	ENZYME
Protein Sub Type	MONOAMINE OXIDASE
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	3OV8HVI592
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AMINE OXIDASE (FLAVIN-CONTAINING) B

Common Name

English

MOA-B

Common Name

English

MAO-B

Common Name

English

MONOAMINE OXIDASE TYPE B

Common Name

English

MONOAMINE OXIDASE B

Common Name

English

MAOB

Common Name

English

MONOAMINE OXIDASE B (HUMAN)

Common Name

English

Code System Code Type Description

UNIPROT

P27338

Created by admin on Sat Dec 16 12:47:55 GMT 2023 , Edited by admin on Sat Dec 16 12:47:55 GMT 2023

PRIMARY

WIKIPEDIA

MONOAMINE OXIDASE B

Created by admin on Sat Dec 16 12:47:55 GMT 2023 , Edited by admin on Sat Dec 16 12:47:55 GMT 2023

PRIMARY

FDA UNII

3OV8HVI592

Created by admin on Sat Dec 16 12:47:55 GMT 2023 , Edited by admin on Sat Dec 16 12:47:55 GMT 2023

PRIMARY

EC (ENZYME CLASS)

EC 1.4.3.4

Created by admin on Sat Dec 16 12:47:55 GMT 2023 , Edited by admin on Sat Dec 16 12:47:55 GMT 2023

PRIMARY

Related Record Type Details


					PCH79KLX33

Tisolagiline

INHIBITOR -> TARGET

Amount:


					LYJ16FZU9Q

CLORGILINE

INHIBITOR -> TARGET

Qualification:

IC50

Amount:


					P2XHC48UCZ

SL-251188 C-11

RADIOLIGAND->TARGET

Amount:


					V1V998DC17

GARLIC

INHIBITOR -> METABOLIC ENZYME

Amount:


					PZV3P03F1U

ATIBEPRONE

INHIBITOR -> TARGET

Amount:


					C045TQL4WP

PHENTERMINE

INHIBITOR -> METABOLIC ENZYME

Amount:


					BF4C9Z1J53

AMANTADINE

INHIBITOR -> METABOLIC ENZYME

Amount:


					U2Z9D55F8E

SMBT-1 F-18

RADIOLIGAND->TARGET

Amount:


					90ENL74SIG

SAFINAMIDE

INHIBITOR -> TARGET

Amount:


					PV4SHR2L8J

4F-Deprenyl

INHIBITOR -> TARGET

Interaction Type:

IRREVERSIBLE INHIBITOR

Amount:


					RG7FY73ZAA

MMDA

INHIBITOR -> METABOLIC ENZYME

Amount:


					6M3C89ZY6R

NICOTINE

INHIBITOR -> METABOLIC ENZYME

Amount:


					K3W9672PNJ

SEMBRAGILINE

INHIBITOR -> TARGET

Amount:


					CK833KGX7E

AMPHETAMINE

INHIBITOR -> METABOLIC ENZYME

Amount:


					T8J7WV7MU5

OCTYLAMINE, C-11

SUBSTRATE->ENZYME

Amount:


					SW3H1USR4Q

LADOSTIGIL

INHIBITOR -> TARGET

Amount:


					Z3867B9SQP

INDANTADOL

INHIBITOR -> TARGET

Amount:


					0HXT24RECU

MILACEMIDE

SUBSTRATE -> METABOLIC ENZYME

Amount:


					YRT54V76ZY

ADARIGILINE

INHIBITOR -> TARGET

Amount:


					Z80293URPV

OZANIMOD

SUBSTRATE -> METABOLIC ENZYME

Amount:


					003N66TS6T

RASAGILINE

INHIBITOR -> TARGET

Amount:


					ISQ9I6J12J

LINEZOLID

INHIBITOR -> METABOLIC ENZYME

Amount:


					90ENL74SIG

SAFINAMIDE

INHIBITOR -> METABOLIC ENZYME

Amount:


					34PHS7TU43

EPICATECHIN

INHIBITOR -> METABOLIC ENZYME

Amount:


					DPF682Q08V

DEPRENYL

INHIBITOR -> TARGET

Interaction Type:

IRREVERSIBLE INHIBITOR

Amount:


					LZ82JLT4UP

VAFIDEMSTAT

INHIBITOR -> TARGET

Amount:


					97HLQ82NGL

TEDIZOLID

INHIBITOR -> METABOLIC ENZYME

Comments:

MAO inhibition can lead to peripheral or central neurotransmitter accumulation, with potentially serious consequences. MAO inhibitors, when taken in combination with vasoconstrictors, such as pseudoephedrine, or high dietary tyramine can cause sudden blood pressure elevations that may lead to hypertensive crises. Combination with serotonergic agents may lead to rare, but potentially life-threatening, serotonin syndrome

Qualification:

IC50

Amount:


					T8J7WV7MU5

OCTYLAMINE, C-11

RADIOLIGAND->TARGET

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER AVERAGE(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL